Open AccessCirculating Tumor DNA Provides a Sneak Peek into Treatment Responses in Non–Small Cell Lung Cancer
Author(s) -
Tong Zou,
Matthew Meyerson
Publication year - 2019
Publication title -
cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.103
H-Index - 449
eISSN - 1538-7445
pISSN - 0008-5472
DOI - 10.1158/0008-5472.can-19-0231
Subject(s) - lung cancer , medicine , circulating tumor dna , cancer , oncology , tyrosine kinase , cancer research , immunotherapy , targeted therapy , receptor
Circulating tumor DNA (ctDNA) holds great promise as a noninvasive diagnostic tool to guide treatment for patients with lung cancer. Two studies by Phallen and colleagues and Anagnostou and colleagues correlated sensitive measures of ctDNA with clinical responses to tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors, respectively, in patients with non-small cell lung cancer (NSCLC). Together, these studies further highlight the potential clinical utility of serial ctDNA monitoring in patients with NSCLC undergoing treatment with both targeted therapies and immunotherapies. See related articles by Phallen et al., p. 1204, and Anagnostou et al., p. 1214 .